Mobocertinib

• Description :

  Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research[1][2].

• Product Name Alternative :

  TAK-788; AP32788

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  EGFR

• Type :

  Reference compound

• Related Pathways :

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/mobocertinib.html

• Purity :

  99.09

• Solubility :

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 80°C)

• Smiles :

  O=C(C1=CN=C(NC2=CC(NC(C=C)=O)=C(N(CCN(C)C)C)C=C2OC)N=C1C3=CN(C)C4=C3C=CC=C4)OC(C)C

• Molecular Formula :

  C32H39N7O4

• Molecular Weight :

  585.70

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Gonzalvez F, et al. Mobocertinib (TAK-788) : A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021 Jul;11 (7) :1672-1687.|[2]Han H, et al. Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. Cancer Res. 2021 Oct 15;81 (20) :5311-5324.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  EGFR/ErbB1/HER1; ErbB2/HER2

• CAS Number :

  [1847461-43-1]